Reserving full karyotyping for the 10% of fetuses with first trimester nuchal translucency (NT) measurements of 4 mm or more and using quantitative fluorescent polymerase chain reaction (qf-PCR) for less suspicious samples may be an effective screening strategy that provides rapid results at significant cost savings, according to a recent observational study.
Reserving full karyotyping for the 10% of fetuses with first trimester nuchal translucency (NT) measurements of 4 mm or more and using quantitative fluorescent polymerase chain reaction (qf-PCR) for less suspicious samples may be an effective screening strategy that provides rapid results at significant cost savings, according to a recent observational study.
Researchers from the United Kingdom evaluated approximately 17,500 chorionic villus samples obtained after assessing risk for trisomy 21 by measurement of fetal NT thickness at 11 to 13 weeks' gestation. They analyzed samples by full karyotyping and by qf-PCR for chromosomes 13, 18, 21, X, and Y.
They found the fetal karyotype to be normal in approximately 89% of cases and abnormal in the remaining 11%. The researchers calculated that while relying entirely on karyotyping reveals all clinically significant chromosomal abnormalities and relying entirely on qf-PCR identifies 97.9%, the combination strategy identifies 99% of significant abnormalities at 60% of the cost of full karyotyping for all.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More